Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, Dec. 15, 2022 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of…

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks